We are live on ! Find out more

VanEck Biotech ETF

BBH

Market cap $470M

234.01 USD

-2.71

1.14%

At close Updated Sep 18, 1:12 PM EDT

1 day

-1.14%

5 days

1.72%

1 month

4.25%

3 months

24.71%

6 months

27.09%

Year to date

23.01%

1 year

39.68%

5 years

9.49%

10 years

100.59%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 38.5%

Neutral 46.2%

Negative 15.4%

5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

5 Undervalued Oncology Stocks Wall Street Is Overlooking

Zacks Investment Research

Should You Invest in the VanEck Biotech ETF (BBH)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December 20, 2011.

Should You Invest in the VanEck Biotech ETF (BBH)?

BBH: Biotech's Next Growth Cycle Is Just Getting Started

VanEck Biotech ETF (BBH) is a Buy, offering concentrated exposure to leading biotech firms entering a new growth cycle. BBH's top holdings—Amgen, Gilead, and Vertex—drive capital appreciation through diversified pipelines, strong cash flows, and expansion into new therapeutic areas. Despite a higher expense ratio and low yield, BBH's risk-reward profile is attractive given enduring demand and robust product pipelines.

BBH: Biotech's Next Growth Cycle Is Just Getting Started

The Motley Fool

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio than VanEck Biotech ETF VanEck Biotech ETF focuses exclusively on 25 biotechnology stocks while State Street Health Care Select Sector SPDR ETF holds 60 diverse healthcare names State Street Health Care Select Sector SPDR ETF has demonstrated higher risk-adjusted growth and a smaller maximum drawdown over the last five years

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?

The Motley Fool

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?

IHE pays a meaningfully higher dividend yield than BBH. BBH offers more concentrated exposure with 25 holdings, compared to 56 for IHE.

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?

The Motley Fool

Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?

Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to the 25 positions in VanEck Biotech ETF VanEck Biotech ETF has a slightly lower expense ratio of 0.35% while Invesco S&P 500 Equal Weight Health Care ETF charges 0.40% Invesco S&P 500 Equal Weight Health Care ETF has experienced a significantly lower five-year maximum drawdown than the biotech fund

Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?

Zacks Investment Research

Should You Invest in the VanEck Biotech ETF (BBH)?

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on December 20, 2011.

Should You Invest in the VanEck Biotech ETF (BBH)?

The Motley Fool

Which is the Better Choice for Healthcare Investors? IYH or BBH?

iShares U.S. Healthcare ETF provides broader exposure with 100 holdings compared to the 25 found in VanEck Biotech ETF VanEck Biotech ETF has delivered higher recent total returns but carries significantly greater historical price volatility iShares U.S. Healthcare ETF offers a higher dividend yield and lower five-year maximum drawdown for income-focused investors

Which is the Better Choice for Healthcare Investors? IYH or BBH?

The Motley Fool

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

State Street SPDR S&P Pharmaceuticals ETF provides exposure to 65 companies compared to the 25 holdings in VanEck Biotech ETF. VanEck Biotech ETF has experienced a deeper maximum drawdown of almost 40% over the last five years.

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The Motley Fool

FHLC vs. BBH: Which Healthcare ETF Is the Better Buy?

Fidelity MSCI Health Care Index ETF (FHLC) provides broad sector exposure with significantly lower fees than VanEck Biotech ETF (BBH). BBH focuses on just 25 holdings in the biotech space while FHLC holds more than 300 positions across the entire healthcare industry.

FHLC vs. BBH: Which Healthcare ETF Is the Better Buy?

See News Rankings

Price charts implemented using Lightweight Charts™